Related Experiment Videos
Aprindine-induced hepatic granulomata
M Elisaf1, S Stefanaki-Nikou, M Voulgarelis
1Department of Internal Medicine, University of Ioannina, Greece.
Journal of Hepatology
|March 1, 1992
Summary
Aprindine, an antiarrhythmic drug, may cause granulomatous hepatitis. This liver condition appeared within weeks of starting aprindine and resolved upon discontinuation, suggesting a causal link.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Aprindine is a potent antiarrhythmic medication.
- It possesses a narrow therapeutic index, requiring careful dosing.
- Adverse drug reactions necessitate ongoing clinical investigation.
Purpose of the Study:
- To report a case of granulomatous hepatitis potentially linked to aprindine use.
- To describe the clinical presentation, resolution, and histological findings associated with this adverse event.
Main Methods:
- Case report detailing a patient's experience with aprindine.
- Clinical observation of hepatitis development and resolution.
- Histopathological examination of liver tissue.
Main Results:
- Granulomatous hepatitis developed within six weeks of aprindine initiation.
- Hepatitis symptoms resolved rapidly after aprindine withdrawal.
- Liver biopsy revealed fibrosis in portal tracts six months post-treatment, without granulomata.
Conclusions:
- Aprindine administration may precipitate granulomatous hepatitis.
- Prompt drug withdrawal is crucial for managing this adverse reaction.
- Long-term liver changes like fibrosis can occur following aprindine-induced hepatitis.